|
1.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 60:277–300. 2010.
|
|
2.
|
Alberg AJ, Ford JG and Samet JM; American
College of Chest Physicians: Epidemiology of lung cancer: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest.
132(Suppl 3): S29–S55. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Dontu G, Liu S and Wicha MS: Stem cells in
mammary development and carcinogenesis: implications for prevention
and treatment. Stem Cell Rev. 1:207–213. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Donnenberg VS and Donnenberg AD: Multiple
drug resistance in cancer revisited: the cancer stem cell
hypothesis. J Clin Pharmacol. 45:872–877. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Toyooka S, Mitsudomi T, Soh J, et al:
Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg.
59:527–537. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
7.
|
Suetsugu A, Nagaki M, Aoki H, Motohashi T,
Kunisada T and Moriwaki H: Characterization of CD133+
hepatocellular carcinoma cells as cancer stem/progenitor cells.
Biochem Biophys Res Commun. 351:820–824. 2006.
|
|
8.
|
Ferrandina G, Bonanno G, Pierelli L, et
al: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J
Gynecol Cancer. 18:506–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kojima M, Ishii G, Atsumi N, Fujii S,
Saito N and Ochiai A: Immunohistochemical detection of CD133
expression in colorectal cancer: a clinicopathological study.
Cancer Sci. 99:1578–1583. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Eramo A, Lotti F, Sette G, et al:
Identification and expansion of the tumorigenic lung cancer stem
cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Janikova M, Skarda J, Dziechciarkova M, et
al: Identification of CD133+/nestin+ putative
cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac
Univ Palacky Olomouc Czech Repub. 154:321–326. 2010.
|
|
12.
|
Cui F, Wang J, Chen D and Chen YJ: CD133
is a temporary marker of cancer stem cells in small cell lung
cancer, but not in non-small cell lung cancer. Oncol Rep.
25:701–708. 2011.PubMed/NCBI
|
|
13.
|
Bertolini G, Roz L, Perego P, et al:
Highly tumorigenic lung cancer CD133+ cells display
stem-like features and are spared by cisplatin treatment. Proc Natl
Acad Sci USA. 106:16281–16286. 2009.PubMed/NCBI
|
|
14.
|
Xu YH, Wang JM, Zhang GB and Hu HC:
Expression and clinical significance of CD133 and B7-H4 in
non-small cell lung cancer. Jiangsu Med J. 4:412–415. 2011.
|
|
15.
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Begg CB and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Cortes-Dericks L, Galetta D, Spaggiari L,
Schmid RA and Karoubi G: High expression of octamer-binding
transcription factor 4A, prominin-1 and aldehyde dehydrogenase
strongly indicates involvement in the initiation of lung
adenocarcinoma resulting in shorter disease-free intervals. Eur J
Cardiothorac Surg. 41:e173–e181. 2012. View Article : Google Scholar
|
|
19.
|
Herpel E, Jensen K, Muley T, et al: The
cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are
not associated with prognosis in resected early-stage non-small
cell lung cancer. Anticancer Res. 31:4491–4500. 2011.PubMed/NCBI
|
|
20.
|
Tirino V, Camerlingo R, Franco R, et al:
The role of CD133 in the identification and characterisation of
tumour-initiating cells in non-small-cell lung cancer. Eur J
Cardiothorac Surg. 36:446–453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Li H, Wang Y, Yu L and Zhao P:
Clinicopathological significance of expression of CD133 protein in
neuroendocrine lung carcinoma tissues. Chin J Cancer Prev Treat.
18:29–31. 2011.
|
|
22.
|
Li F, Zeng H and Ying K: The combination
of stem cell markers CD133 and ABCG2 predicts relapse in stage I
non-small cell lung carcinomas. Med Oncol. 28:1458–1462. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Shien K, Toyooka S, Ichimura K, et al:
Prognostic impact of cancer stem cell-related markers in non-small
cell lung cancer patients treated with induction chemoradiotherapy.
Lung Cancer. 77:162–167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Rivera C, Rivera S, Loriot Y, Vozenin MC
and Deutsch E: Lung cancer stem cell: new insights on experimental
models and preclinical data. J Oncol. 2011:5491812011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Woo T, Okudela K, Mitsui H, et al:
Prognostic value of CD133 expression in stage I lung
adenocarcinomas. Int J Clin Exp Pathol. 4:32–42. 2010.PubMed/NCBI
|
|
26.
|
Wei YP, Wang M, Hua P, et al: Expression
of tumor stem cell marker CD133 in non-small cell lung carcinoma
and its clinical significance. J Sun Yat-Sen Univ (Med Sci).
29:312–316. 2008.
|
|
27.
|
Yao J, Wang ZG, Tong XW, Li ZJ and Yu ZG:
Expression of tumor stem cell marker CD133 and CD44 in original
tumor tissues and metastatic lymph nodes of lung cancer. Med J Natl
Defend Force Southwest China. 20:1300–1303. 2010.
|
|
28.
|
Salnikov AV, Gladkich J, Moldenhauer G,
Volm M, Mattern J and Herr I: CD133 is indicative for a resistance
phenotype but does not represent a prognostic marker for survival
of non-small cell lung cancer patients. Int J Cancer. 126:950–958.
2010.PubMed/NCBI
|
|
29.
|
Lin X, Liu S, Liu N, Yang X, Xu H and Wang
E: Expression and significance of stem cell markers CK19, Notch3,
CD133, P75NTR, STRO-1 and ABCG2 in pulmonary squamous carcinomas.
Zhongguo Fe. 12:316–321. 2009.(In Chinese).
|
|
30.
|
Gu YP, Sun MM, Gu LQ, Zhang H and Xie F:
Expression and significance of cancer stem cell marker CD133, ABCG2
and p75NTR in non-small cell lung carcinoma. Suzhou Univ J Med Sci.
30:513–516. 2010.
|
|
31.
|
Cheng JR, Wang SQ, Zu MRT and Zou J:
Expressions of CD133 and CD105 in lung cancer tissue and their
clinical significance. Tumor. 30:334–337. 2010.
|
|
32.
|
Sun HY, Yang M, Zheng MJ, Ren ZJ and Liu
H: Expression of CD133 and ALDH1 in non-small cell lung cancer and
their clinical significance. J Clin Exp Pathol. 28:813–815.
2012.
|
|
33.
|
Xu LZ and Yang WT: The criteria of
immunohistochemical reaction results. China Oncol. 6:229–231.
1996.
|
